Document is current
Any future updates will be listed below
-
Authors
Itchaki, Gilad https://orcid.org/0000-0002-9064-8139
Bai, Harrison
Tiao, Grace
Improgo, Reina
Oppenheimer, Ben E.
Kasar, Siddha
Tesar, Bethany
Fernandes, Stacey M.
Pochet, Nathalie https://orcid.org/0000-0003-1820-5656
Machado, John-Hanson https://orcid.org/0000-0003-0477-3476
Thrash, Emily M. https://orcid.org/0000-0002-3423-0336
Freedman, Arnold S.
Getz, Gad https://orcid.org/0000-0002-0936-0753
Brown, Jennifer R. https://orcid.org/0000-0003-2040-4961
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258924)
Massachusetts General Hospital (Paul C. Zamecnik Chair in Oncology)
- License Information
-
More Information
Article History
Received: 11 April 2025
Revised: 25 June 2025
Accepted: 14 July 2025
First Online: 28 July 2025
Competing interests
: GI has served as a consultant for AbbVie, Janssen, Astra-Zeneca, Medison, Roche, and Pfizer; received research funding from AbbVie and Janssen; received grants from AbbVie, Sanofi, and Astra-Zenecea. GT is a co-founder and executive of E9 Genomics, Inc. EMT is currently employed by Bio-Techne; previously employed at Olink Proteomics AB, Thermo Fisher Scientific, and Standard BioTools; owns stock in Standard BioTools, Thermo Fisher Scientific, and Bio-Techne. GG receives research funds from IBM, Pharmacyclics/Abbvie, Bayer, Genentech and Ultima Genomics, and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSIDetect, and MinumuMM-seq. He is a founder, consultant, and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in, PreDICTA Biosciences. JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Alloplex Biotherapeutics, BeiGene, Bristol-Myers Squibb, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, InnoCare Pharma Inc, iOnctura, Kite Pharma, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, TG Therapeutics; and serves on the Data Safety Monitoring Board for Grifols Therapeutics. HB, RI, BEO, SK, BT, SMF, NP, JHM, and ASF declares no competing financial interests.
